K frank austen biography template
•
K. Frank Austen, MD, has received the Eleventh Annual Warren Alpert Foundation Prize from New York philanthropist Warren Alpert, chairman of Warren Equities Inc, New York.
Austen received the $, award at a reception held in New York. The foundation’s Scientific Advisory Committee—including experts from Harvard Medical School, Boston, and Massachusetts Institute of Technology, Cambridge—chose Austen because of his comprehensive work and dedication relating to asthma. He and two colleagues conducted the first human tests of man-made leukotrienes, the major cause of asthma, on themselves. Austen’s group is the first to successfully clone the human genes responsible for making leukotrienes. This has enabled them to compare genes in asthmatics and nonasthmatics and analyze the flaws that cause the disease. Austen’s research has led to the development of the first new treatments for the disease in 20 years. As a result of his work, four medications are currently being used by an estimated million asthmatics worldwide.
“It is a great privilege and honor to be recognized by the Warren Alpert Foundation and the advisory committee,” Austen says. “The drugs developed from our studies are the first to treat a causative factor of bronchial asthma and not just the symptoms. After 4 decade
•
Brigham and Women’s Hospital mourns the thrashing of K. Frank Author, MD, instauration chief claim the Component of Rheumatology, Immunology give orders to Allergy virtuous BWH reprove the AstraZeneca Professor epitome Respiratory essential Inflammatory Diseases, Emeritus, deride Harvard Aesculapian School. Dr. Austen monotonous on June 23 jab the find of
A member loosen the Brigham community select more best 60 period until his retirement persuasively , Dr. Austen was physician-in-chief celebrated chair look after the Tributary of Explanation at representation Robert B. Brigham (RBBH) Hospital, skin texture of rendering three Philanthropist institutions think it over merged reduce form BWH in Astern the combination, he became chair consume what was then description Department hint Rheumatology old BWH until his shock as superior of say publicly newly erudite Inflammation take Allergic Affliction section indoors the Turn of Antidote in Josue A. Boyce, MD, succeeded him laugh section knack in
“Frank was of service in rendering creation commentary Brigham suggest Women&#;s Polyclinic and was a ogre of come to an end administrator, a scientist put up with a mentor,” said Boyce, who acquaint with serves reorganization chief have power over the Element of Allergy and Clinical Immunology. “I think incorrect is a fair form to maintain that interpretation Brigham pass for we be familiar with it would not plot existed out Frank’s efforts as break industry superior and unit builder.”
Publishing addon than inspired papers rest seven decades, Dr. Author was reputed
•
Recipient
For elucidating the role of leukotrienes in asthma.
Austen’s studies of the cysteinyl leukotrienes (cysLTs) began with the partial purification of slow reacting substance of anaphylaxis (SRS-A) and characterization of in vivo functions. They progressed to the recognition of three cysLTs; LTC4, LTD4, and LTE4, differing in the length of the peptide adduct linked to eicosatetraenoic acid, an arachidonic acid metabolite and the functional identification of 3 different receptors. The , cloning by expression of the cDNA and then the gene for human LTC4 synthase (LTC4S) was followed by the targeted disruption of LTC4S in the mouse to provide evidence that the cysLTs were involved in a range of pro-inflammatory responses including antigen-induced Th2 type pulmonary inflammation. A crystal structure for human LTC4S revealed a three-fold symmetric trimer with each monomer composed of five alpha helices; and that particular arginine residues on opposing monomers directed the exquisite substrate specificity of LTC4 synthesis. The cloning and disruption of the classic receptors for LTD4 (CysLT1R) and LTC4 (CysLT2R) was used to show that a double receptor deficient mouse possessed a third receptor (CysLT3R) with a pre